OBJECTIVE: To compare radical prostatectomy (RP) vs radiotherapy (RT) with androgen-deprivation therapy (ADT) in the setting of patients with high-risk and very high-risk (VHR) prostate cancer who were deemed eligible for either therapy and made a treatment choice after consultation in a multidisciplinary prostate cancer clinic (MDPCC), and to compare the MDPCC patients' outcomes to a matched Surveillance, Epidemiology and End Results (SEER) cohort. PATIENTS AND METHODS: Prospectively collected, retrospective study comparing patients who underwent RP (231 patients) vs RT+ADT (73) from 2004 to 2013. Biochemical recurrence (BCR), local recurrence, distant metastasis failure, and overall survival (OS) were calculated for each treatment group overall and according to National Comprehensive Cancer Network risk strata. A propensity score matched comparison with a SEER cohort was performed for OS. RESULTS: There was no difference in local recurrence (hazard ratio [HR] 2.7, 95% confidence interval [CI] 1.0-7.9; P = 0.06), distant metastasis failure (HR 2.5, 95% CI 0.8-7.8; P = 0.1) and OS (HR 1.35, 95% CI 0.4-4.8; P = 0.6) between patients undergoing RP vs RT+ADT. Patients treated via the MDPCC survived on average 16.9 months (95% CI 13.1-20.8) longer than those in the matched SEER cohort. CONCLUSIONS: Long-term outcomes appear similar amongst patients with high-risk and VHR prostate cancer deemed eligible for either RP or RT, and treated after consultation in a MDPCC. Outcomes of the MDPCC patients were superior to those of the matched SEER cohort.
OBJECTIVE: To compare radical prostatectomy (RP) vs radiotherapy (RT) with androgen-deprivation therapy (ADT) in the setting of patients with high-risk and very high-risk (VHR) prostate cancer who were deemed eligible for either therapy and made a treatment choice after consultation in a multidisciplinary prostate cancer clinic (MDPCC), and to compare the MDPCC patients' outcomes to a matched Surveillance, Epidemiology and End Results (SEER) cohort. PATIENTS AND METHODS: Prospectively collected, retrospective study comparing patients who underwent RP (231 patients) vs RT+ADT (73) from 2004 to 2013. Biochemical recurrence (BCR), local recurrence, distant metastasis failure, and overall survival (OS) were calculated for each treatment group overall and according to National Comprehensive Cancer Network risk strata. A propensity score matched comparison with a SEER cohort was performed for OS. RESULTS: There was no difference in local recurrence (hazard ratio [HR] 2.7, 95% confidence interval [CI] 1.0-7.9; P = 0.06), distant metastasis failure (HR 2.5, 95% CI 0.8-7.8; P = 0.1) and OS (HR 1.35, 95% CI 0.4-4.8; P = 0.6) between patients undergoing RP vs RT+ADT. Patients treated via the MDPCC survived on average 16.9 months (95% CI 13.1-20.8) longer than those in the matched SEER cohort. CONCLUSIONS: Long-term outcomes appear similar amongst patients with high-risk and VHR prostate cancer deemed eligible for either RP or RT, and treated after consultation in a MDPCC. Outcomes of the MDPCC patients were superior to those of the matched SEER cohort.
Authors: Jianqing Lin; Robert B Den; Jacob Greenspan; Timothy N Showalter; Jean H Hoffman-Censits; Costas D Lallas; Edouard J Trabulsi; Leonard G Gomella; Mark D Hurwitz; Benjamin Leiby; Adam P Dicker; W Kevin Kelly Journal: Int J Radiat Oncol Biol Phys Date: 2020-02-03 Impact factor: 7.038
Authors: David Guy; Rachel Glicksman; Roger Buckley; Patrick Cheung; Hans Chung; Stanley Flax; David Hajek; Andrew Loblaw; Gerard Morton; Jeffery Noakes; Les Spevack; Joseph L K Chin; George Rodrigues Journal: Can Urol Assoc J Date: 2022-04 Impact factor: 2.052
Authors: Abdulmajeed Aydh; Reza Sari Motlagh; Mohammad Abufaraj; Keiichiro Mori; Satoshi Katayama; Nico Grossmann; Pawel Rajwa; Hadi Mostafai; Ekaterina Laukhtina; Benjamin Pradere; Fahad Quhal; Victor M Schuettfort; Alberto Briganti; Pierre I Karakiewicz; Haron Fajkovic; Shahrokh F Shariat Journal: Arab J Urol Date: 2022-03-30
Authors: Nynikka R Palmer; Janet K Shim; Celia P Kaplan; Dean Schillinger; Sarah D Blaschko; Benjamin N Breyer; Rena J Pasick Journal: BMJ Open Date: 2020-08-05 Impact factor: 2.692
Authors: Alexander F Bagley; Mitchell S Anscher; Seungtaek Choi; Steven J Frank; Karen E Hoffman; Deborah A Kuban; Sean E McGuire; Quynh-Nhu Nguyen; Brian Chapin; Ana Aparicio; Todd A Pezzi; Grace L Smith; Benjamin D Smith; Kenneth Hess; Chad Tang Journal: JAMA Netw Open Date: 2020-03-02
Authors: Stefan A Koerber; Johannes Boesch; Clemens Kratochwil; Ingmar Schlampp; Jonas Ristau; Erik Winter; Stefanie Zschaebitz; Luisa Hofer; Klaus Herfarth; Klaus Kopka; Tim Holland-Letz; Dirk Jaeger; Markus Hohenfellner; Uwe Haberkorn; Juergen Debus; Frederik L Giesel Journal: Cancers (Basel) Date: 2021-03-25 Impact factor: 6.639